{"id":"enoxaparin-placebo-syringe","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Enoxaparin placebo syringe","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:56:10.239144+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:56:16.722031+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Enoxaparin placebo syringe","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:56:17.458471+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Antithrombin-III activator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:56:18.211685+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201476/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:56:18.100241+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin placebo syringe is an inert comparator product designed for blinded clinical studies evaluating enoxaparin (a low-molecular-weight heparin anticoagulant). The placebo mimics the appearance and administration route of active enoxaparin but delivers no therapeutic effect, allowing researchers to isolate the true efficacy of the active drug from placebo response.","oneSentence":"This is a placebo syringe formulation used as a control in clinical trials; it contains no active pharmaceutical ingredient.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:29.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:56:19.913508+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Clinical trial control comparator for enoxaparin studies (not a therapeutic product)"}]},"trialDetails":[{"nctId":"NCT03664180","phase":"PHASE4","title":"Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2019-01-11","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":2989},{"nctId":"NCT02379806","phase":"PHASE3","title":"The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2015-09-03","conditions":"Venous Thromboembolism","enrollment":2560},{"nctId":"NCT04558125","phase":"PHASE4","title":"Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-09-08","conditions":"Pulmonary Embolism, COVID","enrollment":2},{"nctId":"NCT03841396","phase":"PHASE4","title":"A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers.","status":"COMPLETED","sponsor":"Aspen Global Incorporated","startDate":"2016-06-02","conditions":"Injection Site Reaction","enrollment":15},{"nctId":"NCT02401594","phase":"PHASE3","title":"PROphylaxis in NOn Major Orthopaedic Surgery","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-12-08","conditions":"Non-major Orthopaedic Surgery","enrollment":3608},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT00371683","phase":"PHASE3","title":"Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-11","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":3608},{"nctId":"NCT00457002","phase":"PHASE3","title":"Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-06","conditions":"Venous Thrombosis, Pulmonary Embolism","enrollment":6758},{"nctId":"NCT00362232","phase":"PHASE3","title":"Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-06","conditions":"Venous Thromboembolism","enrollment":3148},{"nctId":"NCT00396786","phase":"PHASE2","title":"Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-11","conditions":"Venous Thromboembolism","enrollment":877},{"nctId":"NCT00679588","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-04","conditions":"Venous Thromboembolism","enrollment":4413},{"nctId":"NCT00721760","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Venous Thromboembolism","enrollment":1003},{"nctId":"NCT00697099","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Venous Thromboembolism","enrollment":2326},{"nctId":"NCT00718224","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Venous Thromboembolism","enrollment":1150},{"nctId":"NCT00331838","phase":"PHASE2","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Venous Thromboembolism","enrollment":705}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1201476"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Enoxaparin placebo syringe","genericName":"Enoxaparin placebo syringe","companyName":"Beijing Anzhen Hospital","companyId":"beijing-anzhen-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo syringe formulation used as a control in clinical trials; it contains no active pharmaceutical ingredient. Used for Clinical trial control comparator for enoxaparin studies (not a therapeutic product).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:56:19.913508+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}